Latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer – Pipeline Review, H1 2018, provides an overview of the Ovarian Cancer pipeline landscape. Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Ovarian Cancer , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ovarian Cancer pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are:- 4, 2, 15, 135, 128, 7, 208, 21 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 14, 43 and 8 molecules, respectively.
Ovarian Cancer pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies Mentioned in Ovarian Cancer are: 3-V Biosciences Inc, 4SC AG, AB Science SA, AbbVie Inc, AbGenomics International Inc, Adaptimmune Therapeutics Plc, Adgero Biopharmaceuticals Holdings Inc, Advanced Cancer Therapeutics LLC, Advantagene Inc, Advenchen Laboratories LLC, Aeterna Zentaris Inc, Alethia Biotherapeutics Inc, AlfaSigma SpA, Alkermes Plc, Allist Shanghai Pharmaceutical Technology Co Ltd, Almac Discovery Ltd, Alpha Cancer Technologies Inc, Alteogen Inc, Altor BioScience Corp, Ambrx Inc, Amgen Inc, Amunix Operating Inc, Anavex Life Sciences Corp, ANP Technologies Inc, AntiCancer Inc, Antigen Express Inc, Antoxis Ltd, Aphios Corp, Aposense Ltd, Aprea AB, arGEN-X BV, ARMO Biosciences Inc, Armour Therapeutics Inc, ArQule Inc, Array BioPharma Inc, Arrien Pharmaceuticals LLC, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, Atara Biotherapeutics Inc, Athenex Inc, AVEO Pharmaceuticals Inc, Avipep Pty Ltd, Basilea Pharmaceutica Ltd, Bavarian Nordic A/S, Bayer AG, BeiGene Ltd, Bio-Path Holdings Inc, BioCancell Ltd, BioMoti Ltd, Bionomics Ltd, BioNTech AG, Biscayne Pharmaceuticals Inc, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Co, Caladrius Biosciences Inc, Calithera Biosciences Inc, CASI Pharmaceuticals Inc, Cavion LLC, CBT Pharmaceuticals Inc, Celgene Corp, Celldex Therapeutics Inc, Celleron Therapeutics Ltd, Cellular Biomedicine Group Inc, Celon Pharma SA, Celprogen Inc, Celsion Corp, Celyad SA, Ceronco Biosciences, CerRx Inc, Chipscreen Biosciences Ltd, Cielo Therapeutics Inc, Clovis Oncology Inc, CohBar Inc, Coherus BioSciences Inc, Commence Bio Inc, Compliment Corp, Corcept Therapeutics Inc, Critical Outcome Technologies Inc, Cyclacel Pharmaceuticals Inc, CytomX Therapeutics Inc, Cytori Therapeutics Inc, CZ BioMed Corp, DAE HWA Pharmaceutical Co Ltd, Deciphera Pharmaceuticals LLC, DEKK-TEC Inc, DelMar Pharmaceuticals Inc, Dr. Reddy’s Laboratories Ltd, Ecrins Therapeutics SAS, Eisai Co Ltd, Eli Lilly and Co, Endocyte Inc, EntreChem SL, Epigen Biosciences Inc, EpiThany Inc, Epizyme Inc, Esperance Pharmaceuticals Inc, Exelixis Inc, F. Hoffmann-La Roche Ltd, Faron Pharmaceuticals Oy, Fate Therapeutics Inc, Forty Seven Inc, Fujifilm Holdings Corporation, Galena Biopharma Inc, GamaMabs Pharma SA, Gene Techno Science Co Ltd, Genelux Corp, Genentech Inc, Genisphere LLC, Genmab A/S, Genor BioPharma Co Ltd, Gilead Sciences Inc, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, GlycoNex Inc, Glycotope GmbH, GP Pharm SA, Gradalis Inc, GW Pharmaceuticals Plc, Halozyme Therapeutics Inc, Hanmi Pharmaceuticals Co Ltd, Hemispherx Biopharma Inc, Horizon Pharma Plc, Ideaya Biosciences Inc, Ignyta Inc, Ildong Pharmaceutical Co Ltd, IMMD Inc, Immix BioPharma Inc, Immune Design Corp, Immune Pharmaceuticals Inc, Immunocore Ltd, ImmunoGen Inc, Immunomedics Inc, Immunovaccine Inc, IMPACT Therapeutics Inc, Imugene Ltd, Incyte Corp, Innate Pharma SA, Innovation Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, Inventiva, Iovance Biotherapeutics Inc, ITUS Corp, Jiangsu Hengrui Medicine Co Ltd, Jiangsu Kanion Pharmaceutical Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Karyopharm Therapeutics Inc, Kazia Therapeutics Ltd, Kringle Pharma Inc, Kyowa Hakko Kirin Co Ltd, La Jolla Pharmaceutical Company, Laboratoire HRA Pharma SAS, Lantern Pharma Inc, LATITUDE Pharmaceuticals Inc, LegoChem Biosciences Inc, Lidds AB, Lixte Biotechnology Holdings Inc, Loxo Oncology Inc, Lycera Corp, Lymphocyte Activation Technologies SA, MabVax Therapeutics Holdings Inc, MacroGenics Inc, Madrigal Pharmaceuticals Inc., Mateon Therapeutics Inc, MaxiVAX SA, Mebiopharm Co Ltd, MediaPharma SRL, MedImmune LLC, Medivir AB, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Mersana Therapeutics Inc, Merus NV, Microlin Bio Inc, Millennium Pharmaceuticals Inc, Minerva Biotechnologies Corp, Moleculin Biotech Inc, MolMed SpA, Monopar Therapeutics LLC, Morphotek Inc, Mycenax Biotech Inc, NanoVector Inc, NantKwest Inc, Natco Pharma Ltd, NBE-Therapeutics AG, Nektar Therapeutics, Neovacs SA, Nerviano Medical Sciences Srl, Neurimmune Holding AG, NewLink Genetics Corp, Northwest Biotherapeutics Inc, Novartis AG, NovaTarg Therapeutics Inc, Noviga Research AB, Noxopharm Ltd, NuCana Plc, Oasmia Pharmaceutical AB, OBI Pharma Inc, Omeros Corp, Omnitura Therapeutics Inc, OncBioMune Pharmaceuticals Inc, Oncobiologics Inc, Oncodesign SA, Oncolix Inc, Oncolytics Biotech Inc, OncoMed Pharmaceuticals Inc, OncoResponse Inc, OncoTartis Inc, OncoTherapy Science Inc, Oncternal Therapeutics Inc, Ono Pharmaceutical Co Ltd, Opsona Therapeutics Ltd, Optimum Therapeutics LLC, ORCA Therapeutics BV, Oric Pharmaceuticals Inc, OSE Immunotherapeutics, Oxford BioMedica Plc, Pangaea Biotech SL, Patrys Ltd, PDS Biotechnology Corp, PEP-Therapy SAS, Pfizer Inc, Pharma Mar SA, PharmAust Ltd, Pharmicell Co Ltd, Plexxikon Inc, Polaris Pharmaceuticals Inc, Precision Biologics Inc, Propanc Biopharma Inc, Protheragen Inc, PsiOxus Therapeutics Ltd, PTC Therapeutics Inc, Puma Biotechnology Inc, Radius Health Inc, Recepta Biopharma SA, Rexahn Pharmaceuticals Inc, Rgenix Inc, Richter Gedeon Nyrt, Rigel Pharmaceuticals Inc, Rosetta Genomics Ltd, RS Research, Rubicon Biotechnology Inc, RXi Pharmaceuticals Corp, Samumed LLC, Sanofi, Sanofi Pasteur SA, SATT North SAS, Scancell Holdings Plc, Sellas Life Sciences Group Ltd, Senhwa Biosciences Inc, Sequoia Sciences Inc, Siamab Therapeutics Inc, Sierra Oncology Inc, Sigma-Tau SpA, Sillajen Biotherapeutics, Sitka Biopharma Inc, Soricimed Biopharma Inc, Sorrento Therapeutics Inc, Sotio AS, Starpharma Holdings Ltd, Sumitomo Dainippon Pharma Co Ltd, Sun Pharma Advanced Research Company Ltd, Supratek Pharma Inc, Susavion Biosciences Inc, Sutro Biopharma Inc, Syndax Pharmaceuticals Inc, Synthon Holdings BV, Syros Pharmaceuticals Inc, Tactiva Therapeutics LLC, Taiho Pharmaceutical Co Ltd, Takis Srl, TapImmune Inc, Targovax ASA, TC BioPharm Ltd, Tesaro Inc, The Female Health Company, TheraTarget Inc, Tocagen Inc, TRACON Pharmaceuticals Inc, Transgene SA, TVAX Biomedical Inc, Tyrogenex Inc, Unleash Immuno Oncolytics Inc, ValiRx Plc, Vascular Biogenics Ltd, Vectorite Biomedical Inc, Verastem Inc, VG Life Sciences Inc, ViiV Healthcare UK Ltd, ViraTherapeutics GmbH, Vyriad Inc, Zymeworks Inc
Request for a Sample Copy of this Research Report at: https://www.marketinsightsreports.com/reports/07055844/ovarian-cancer-pipeline-review-h1-2017/inquiry?source=apexnews&Mode=01
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer.
2. The pipeline guide reviews pipeline therapeutics for Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources.
3. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
4. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
5. The pipeline guide reviews key companies involved in Ovarian Cancer therapeutics and enlists all their major and minor projects.
6. The pipeline guide evaluates Ovarian Cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
7. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
8. The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer
The objective of updating report coverage is to ensure that it represents the most up to date vision of the industry possible. The report covers all the pharmaceutical/biopharmaceutical products under development across the globe. The scope of the pipeline products coverage aims at setting up the boundaries of the project. It comprises all the therapeutic Products that are in the course of development, however, if a drug is solely used for research purpose, where the Intention for its further development as a drug is not clear or the strategy for commercialization is not known, the drug is not included in the report. Our aims to cover major news events and deals in the pharmaceutical Industry, updated on daily basis. The coverage is further streamlined and strengthened with additional inputs from our Expert Panel.
Important Points Covered In Table of Content are:
Therapeutics Assessment, Assessment by Target, Assessment by Mechanism of Action, Assessment by Route of Administration, Assessment by Molecule Type, Pipeline Overview, Pipeline by Companies, Pipeline by Universities/Institutes, Products under Development by Companies, Products under Development by Universities/Institutes.
List of Tables Mentioned are:
1) Number of Products under Development for Ovarian Cancer, H1 2018, 2) Number of Products under Development by Companies, H1 2018, 3) Number of Products under Development by Universities/Institutes, H1 2018, 4) Products under Development by Companies, H1 2018, 5) Products under Development by Universities/Institutes, H1 2018, 6) Number of Products by Stage and Target, H1 2018, 7) Number of Products by Stage and Mechanism of Action, H1 2018, 8) Number of Products by Stage and Route of Administration, H1 2018, 9) Number of Products by Stage and Molecule Type, H1 2018